Evidence
Continuous Glucose Monitoring Initiation Within First Year of Type 1 Diabetes Diagnosis Is Associated With Improved Glycemic Outcomes: 7-Year Follow-Up Study
January 12, 2022Clinical Outcomes Article / PublicationLearn MoreJanuary 4, 2022Clinical Outcomes Featured News & Info Video
October 22, 2021Coverage and Benefit Design Article / Publication / CGM Best Practices
Managed Care Insights Brief
October 11, 2021Clinical Outcomes Article / Publication
Source: Endocrine Today
“Our real-world study found that in patients with insulin-treated diabetes, initiating a continuous glucose monitor substantially improved blood glucose control and cut the rate of emergency room visits for hypoglycemia in half,”
Andre J . Karter, PhD
Learn MoreSeptember 29, 2021CGM Technology and Digital Health Article / Publication
Source: Diabetes Technology & Therapeutics
Published: September 2021
Learn MoreLower A1c and Reduce Hospital/ED Use in Members with Insulin-Treated Type 2 Diabetes via Real-Time Continuous Glucose Monitoring
September 16, 2021Clinical Outcomes Economic Outcomes Infographic
Optimize Outcomes in Insulin-Treated T1 and T2D via Evidence-Based Coverage Criteria with Real-Time Continuous Glucose Monitoring
September 16, 2021Clinical Outcomes Coverage and Benefit Design Economic Outcomes Infographic
Association Between Real-Time Continuous Glucose Monitor Use and Diabetes-Related Medical Costs for Patients with Type 2 Diabetes
September 2, 2021Clinical Outcomes Economic Outcomes Article / PublicationLearn MoreReal-World Studies Support Use of Continuous Glucose Monitoring in Type 1 and Type 2 Diabetes Independently of Treatment Regimen
September 2, 2021Clinical Outcomes Article / PublicationLearn MoreReal-Time Continuous Glucose Monitor (RTCGM) Use Associated with Decreased Diabetes Medical Costs for Patients with Type 2 Diabetes (T2D)
August 9, 2021Economic Outcomes Article / Publication
Source: Digital Technology and Therapeutics
Key Takeaway: A retrospective analysis of administrative claims data from the Optum Research Database showed rtCGM use was associated with diabetes-related medical cost reductions in patients with T2D. Increased access to rtCGM for patients with T2D may help to reduce diabetes-related cost of care.
Diabetes-related Medical Care Costs Decreased $424 PPPM After Initiating rtCGM Treatment
*PPPM = per patient per month
Learn More
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
Continuous Glucose Monitoring Initiation Within First Year of Type 1 Diabetes Diagnosis Is Associated With Improved Glycemic Outcomes: 7-Year Follow-Up Study
January 4, 2022Clinical Outcomes Featured News & Info Video
October 22, 2021Coverage and Benefit Design Article / Publication / CGM Best Practices
Managed Care Insights Brief
Learn MoreOctober 11, 2021Clinical Outcomes Article / Publication
Source: Endocrine Today
“Our real-world study found that in patients with insulin-treated diabetes, initiating a continuous glucose monitor substantially improved blood glucose control and cut the rate of emergency room visits for hypoglycemia in half,”
Andre J . Karter, PhD
Learn MoreSeptember 29, 2021CGM Technology and Digital Health Article / Publication
Source: Diabetes Technology & Therapeutics
Published: September 2021
Learn MoreLower A1c and Reduce Hospital/ED Use in Members with Insulin-Treated Type 2 Diabetes via Real-Time Continuous Glucose Monitoring
September 16, 2021Clinical Outcomes Economic Outcomes Infographic
Learn MoreOptimize Outcomes in Insulin-Treated T1 and T2D via Evidence-Based Coverage Criteria with Real-Time Continuous Glucose Monitoring
September 16, 2021Clinical Outcomes Coverage and Benefit Design Economic Outcomes Infographic
Learn MoreAssociation Between Real-Time Continuous Glucose Monitor Use and Diabetes-Related Medical Costs for Patients with Type 2 Diabetes
September 2, 2021Clinical Outcomes Economic Outcomes Article / PublicationLearn MoreReal-World Studies Support Use of Continuous Glucose Monitoring in Type 1 and Type 2 Diabetes Independently of Treatment Regimen
September 2, 2021Clinical Outcomes Article / PublicationLearn MoreReal-Time Continuous Glucose Monitor (RTCGM) Use Associated with Decreased Diabetes Medical Costs for Patients with Type 2 Diabetes (T2D)
August 9, 2021Economic Outcomes Article / Publication
Source: Digital Technology and Therapeutics
Key Takeaway: A retrospective analysis of administrative claims data from the Optum Research Database showed rtCGM use was associated with diabetes-related medical cost reductions in patients with T2D. Increased access to rtCGM for patients with T2D may help to reduce diabetes-related cost of care.
Diabetes-related Medical Care Costs Decreased $424 PPPM After Initiating rtCGM Treatment
*PPPM = per patient per month
Learn More
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
October 22, 2021Coverage and Benefit Design Article / Publication / CGM Best Practices
Managed Care Insights Brief
Learn MoreOctober 11, 2021Clinical Outcomes Article / Publication
Source: Endocrine Today
“Our real-world study found that in patients with insulin-treated diabetes, initiating a continuous glucose monitor substantially improved blood glucose control and cut the rate of emergency room visits for hypoglycemia in half,”
Andre J . Karter, PhD
Learn MoreSeptember 29, 2021CGM Technology and Digital Health Article / Publication
Source: Diabetes Technology & Therapeutics
Published: September 2021
Learn MoreLower A1c and Reduce Hospital/ED Use in Members with Insulin-Treated Type 2 Diabetes via Real-Time Continuous Glucose Monitoring
September 16, 2021Clinical Outcomes Economic Outcomes Infographic
Learn MoreOptimize Outcomes in Insulin-Treated T1 and T2D via Evidence-Based Coverage Criteria with Real-Time Continuous Glucose Monitoring
September 16, 2021Clinical Outcomes Coverage and Benefit Design Economic Outcomes Infographic
Learn MoreAssociation Between Real-Time Continuous Glucose Monitor Use and Diabetes-Related Medical Costs for Patients with Type 2 Diabetes
September 2, 2021Clinical Outcomes Economic Outcomes Article / PublicationLearn MoreReal-World Studies Support Use of Continuous Glucose Monitoring in Type 1 and Type 2 Diabetes Independently of Treatment Regimen
September 2, 2021Clinical Outcomes Article / PublicationLearn MoreReal-Time Continuous Glucose Monitor (RTCGM) Use Associated with Decreased Diabetes Medical Costs for Patients with Type 2 Diabetes (T2D)
August 9, 2021Economic Outcomes Article / Publication
Source: Digital Technology and Therapeutics
Key Takeaway: A retrospective analysis of administrative claims data from the Optum Research Database showed rtCGM use was associated with diabetes-related medical cost reductions in patients with T2D. Increased access to rtCGM for patients with T2D may help to reduce diabetes-related cost of care.
Diabetes-related Medical Care Costs Decreased $424 PPPM After Initiating rtCGM Treatment
*PPPM = per patient per month
Learn More
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
Managed Care Insights Brief
October 11, 2021Clinical Outcomes Article / Publication
Source: Endocrine Today
“Our real-world study found that in patients with insulin-treated diabetes, initiating a continuous glucose monitor substantially improved blood glucose control and cut the rate of emergency room visits for hypoglycemia in half,”
Andre J . Karter, PhD
Learn MoreSeptember 29, 2021CGM Technology and Digital Health Article / Publication
Source: Diabetes Technology & Therapeutics
Published: September 2021
Learn MoreLower A1c and Reduce Hospital/ED Use in Members with Insulin-Treated Type 2 Diabetes via Real-Time Continuous Glucose Monitoring
September 16, 2021Clinical Outcomes Economic Outcomes Infographic
Learn MoreOptimize Outcomes in Insulin-Treated T1 and T2D via Evidence-Based Coverage Criteria with Real-Time Continuous Glucose Monitoring
September 16, 2021Clinical Outcomes Coverage and Benefit Design Economic Outcomes Infographic
Learn MoreAssociation Between Real-Time Continuous Glucose Monitor Use and Diabetes-Related Medical Costs for Patients with Type 2 Diabetes
September 2, 2021Clinical Outcomes Economic Outcomes Article / PublicationLearn MoreReal-World Studies Support Use of Continuous Glucose Monitoring in Type 1 and Type 2 Diabetes Independently of Treatment Regimen
September 2, 2021Clinical Outcomes Article / PublicationLearn MoreReal-Time Continuous Glucose Monitor (RTCGM) Use Associated with Decreased Diabetes Medical Costs for Patients with Type 2 Diabetes (T2D)
August 9, 2021Economic Outcomes Article / Publication
Source: Digital Technology and Therapeutics
Key Takeaway: A retrospective analysis of administrative claims data from the Optum Research Database showed rtCGM use was associated with diabetes-related medical cost reductions in patients with T2D. Increased access to rtCGM for patients with T2D may help to reduce diabetes-related cost of care.
Diabetes-related Medical Care Costs Decreased $424 PPPM After Initiating rtCGM Treatment
*PPPM = per patient per month
Learn More
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
Source: Endocrine Today
“Our real-world study found that in patients with insulin-treated diabetes, initiating a continuous glucose monitor substantially improved blood glucose control and cut the rate of emergency room visits for hypoglycemia in half,”
Andre J . Karter, PhD
Learn More
September 29, 2021CGM Technology and Digital Health Article / Publication
Source: Diabetes Technology & Therapeutics
Published: September 2021
Learn MoreLower A1c and Reduce Hospital/ED Use in Members with Insulin-Treated Type 2 Diabetes via Real-Time Continuous Glucose Monitoring
September 16, 2021Clinical Outcomes Economic Outcomes Infographic
Learn MoreOptimize Outcomes in Insulin-Treated T1 and T2D via Evidence-Based Coverage Criteria with Real-Time Continuous Glucose Monitoring
September 16, 2021Clinical Outcomes Coverage and Benefit Design Economic Outcomes Infographic
Learn MoreAssociation Between Real-Time Continuous Glucose Monitor Use and Diabetes-Related Medical Costs for Patients with Type 2 Diabetes
September 2, 2021Clinical Outcomes Economic Outcomes Article / PublicationLearn MoreReal-World Studies Support Use of Continuous Glucose Monitoring in Type 1 and Type 2 Diabetes Independently of Treatment Regimen
September 2, 2021Clinical Outcomes Article / PublicationLearn MoreReal-Time Continuous Glucose Monitor (RTCGM) Use Associated with Decreased Diabetes Medical Costs for Patients with Type 2 Diabetes (T2D)
August 9, 2021Economic Outcomes Article / Publication
Source: Digital Technology and Therapeutics
Key Takeaway: A retrospective analysis of administrative claims data from the Optum Research Database showed rtCGM use was associated with diabetes-related medical cost reductions in patients with T2D. Increased access to rtCGM for patients with T2D may help to reduce diabetes-related cost of care.
Diabetes-related Medical Care Costs Decreased $424 PPPM After Initiating rtCGM Treatment
*PPPM = per patient per month
Learn More
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
Source: Diabetes Technology & Therapeutics
Published: September 2021
Learn MoreLower A1c and Reduce Hospital/ED Use in Members with Insulin-Treated Type 2 Diabetes via Real-Time Continuous Glucose Monitoring
September 16, 2021Clinical Outcomes Economic Outcomes Infographic
Learn MoreOptimize Outcomes in Insulin-Treated T1 and T2D via Evidence-Based Coverage Criteria with Real-Time Continuous Glucose Monitoring
September 16, 2021Clinical Outcomes Coverage and Benefit Design Economic Outcomes Infographic
Learn MoreAssociation Between Real-Time Continuous Glucose Monitor Use and Diabetes-Related Medical Costs for Patients with Type 2 Diabetes
September 2, 2021Clinical Outcomes Economic Outcomes Article / PublicationLearn MoreReal-World Studies Support Use of Continuous Glucose Monitoring in Type 1 and Type 2 Diabetes Independently of Treatment Regimen
September 2, 2021Clinical Outcomes Article / PublicationLearn MoreReal-Time Continuous Glucose Monitor (RTCGM) Use Associated with Decreased Diabetes Medical Costs for Patients with Type 2 Diabetes (T2D)
August 9, 2021Economic Outcomes Article / Publication
Source: Digital Technology and Therapeutics
Key Takeaway: A retrospective analysis of administrative claims data from the Optum Research Database showed rtCGM use was associated with diabetes-related medical cost reductions in patients with T2D. Increased access to rtCGM for patients with T2D may help to reduce diabetes-related cost of care.
Diabetes-related Medical Care Costs Decreased $424 PPPM After Initiating rtCGM Treatment
*PPPM = per patient per month
Learn More
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
Lower A1c and Reduce Hospital/ED Use in Members with Insulin-Treated Type 2 Diabetes via Real-Time Continuous Glucose Monitoring
Optimize Outcomes in Insulin-Treated T1 and T2D via Evidence-Based Coverage Criteria with Real-Time Continuous Glucose Monitoring
September 16, 2021Clinical Outcomes Coverage and Benefit Design Economic Outcomes Infographic
Learn MoreAssociation Between Real-Time Continuous Glucose Monitor Use and Diabetes-Related Medical Costs for Patients with Type 2 Diabetes
September 2, 2021Clinical Outcomes Economic Outcomes Article / PublicationLearn MoreReal-World Studies Support Use of Continuous Glucose Monitoring in Type 1 and Type 2 Diabetes Independently of Treatment Regimen
September 2, 2021Clinical Outcomes Article / PublicationLearn MoreReal-Time Continuous Glucose Monitor (RTCGM) Use Associated with Decreased Diabetes Medical Costs for Patients with Type 2 Diabetes (T2D)
August 9, 2021Economic Outcomes Article / Publication
Source: Digital Technology and Therapeutics
Key Takeaway: A retrospective analysis of administrative claims data from the Optum Research Database showed rtCGM use was associated with diabetes-related medical cost reductions in patients with T2D. Increased access to rtCGM for patients with T2D may help to reduce diabetes-related cost of care.
Diabetes-related Medical Care Costs Decreased $424 PPPM After Initiating rtCGM Treatment
*PPPM = per patient per month
Learn More
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
Optimize Outcomes in Insulin-Treated T1 and T2D via Evidence-Based Coverage Criteria with Real-Time Continuous Glucose Monitoring
Association Between Real-Time Continuous Glucose Monitor Use and Diabetes-Related Medical Costs for Patients with Type 2 Diabetes
September 2, 2021Clinical Outcomes Economic Outcomes Article / PublicationLearn MoreReal-World Studies Support Use of Continuous Glucose Monitoring in Type 1 and Type 2 Diabetes Independently of Treatment Regimen
September 2, 2021Clinical Outcomes Article / PublicationLearn MoreReal-Time Continuous Glucose Monitor (RTCGM) Use Associated with Decreased Diabetes Medical Costs for Patients with Type 2 Diabetes (T2D)
August 9, 2021Economic Outcomes Article / Publication
Source: Digital Technology and Therapeutics
Key Takeaway: A retrospective analysis of administrative claims data from the Optum Research Database showed rtCGM use was associated with diabetes-related medical cost reductions in patients with T2D. Increased access to rtCGM for patients with T2D may help to reduce diabetes-related cost of care.
Diabetes-related Medical Care Costs Decreased $424 PPPM After Initiating rtCGM Treatment
*PPPM = per patient per month
Learn More
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources
Association Between Real-Time Continuous Glucose Monitor Use and Diabetes-Related Medical Costs for Patients with Type 2 Diabetes
Real-World Studies Support Use of Continuous Glucose Monitoring in Type 1 and Type 2 Diabetes Independently of Treatment Regimen
September 2, 2021Clinical Outcomes Article / PublicationLearn MoreReal-Time Continuous Glucose Monitor (RTCGM) Use Associated with Decreased Diabetes Medical Costs for Patients with Type 2 Diabetes (T2D)
August 9, 2021Economic Outcomes Article / Publication
Source: Digital Technology and Therapeutics
Key Takeaway: A retrospective analysis of administrative claims data from the Optum Research Database showed rtCGM use was associated with diabetes-related medical cost reductions in patients with T2D. Increased access to rtCGM for patients with T2D may help to reduce diabetes-related cost of care.
Diabetes-related Medical Care Costs Decreased $424 PPPM After Initiating rtCGM Treatment
*PPPM = per patient per month
Learn More
Real-World Studies Support Use of Continuous Glucose Monitoring in Type 1 and Type 2 Diabetes Independently of Treatment Regimen
Real-Time Continuous Glucose Monitor (RTCGM) Use Associated with Decreased Diabetes Medical Costs for Patients with Type 2 Diabetes (T2D)
August 9, 2021Economic Outcomes Article / Publication
Source: Digital Technology and Therapeutics
Key Takeaway: A retrospective analysis of administrative claims data from the Optum Research Database showed rtCGM use was associated with diabetes-related medical cost reductions in patients with T2D. Increased access to rtCGM for patients with T2D may help to reduce diabetes-related cost of care.
Diabetes-related Medical Care Costs Decreased $424 PPPM After Initiating rtCGM Treatment
*PPPM = per patient per month
Learn More
Real-Time Continuous Glucose Monitor (RTCGM) Use Associated with Decreased Diabetes Medical Costs for Patients with Type 2 Diabetes (T2D)
Source: Digital Technology and Therapeutics
Key Takeaway: A retrospective analysis of administrative claims data from the Optum Research Database showed rtCGM use was associated with diabetes-related medical cost reductions in patients with T2D. Increased access to rtCGM for patients with T2D may help to reduce diabetes-related cost of care.
Diabetes-related Medical Care Costs Decreased $424 PPPM After Initiating rtCGM Treatment
*PPPM = per patient per month
Learn More